DALY and HLY in Portugal, 1990–2019. The first graph shows a decreasing trend of DALY and the second graph shows an increasing trend of HLY. by Aida Isabel Tavares (12080156)

Receiver operating characteristic curve analyses for the prediction of hepatitis C. by Lu Han (151620)

Subjects:

Effects of bevacizumab addition on VEGF-A concentrations <i>in vitro</i>. by Masashi Okawa (8951294)

Subjects:

Uronic acid analysis-based screen identified IFA as an effective capsule inhibitor. by Tingting Wang (123983)

Subjects:

IFA did not affect LPS-induced inflammation response. by Tingting Wang (123983)

Subjects:

IFA reduced the capsular biosynthesis through altering bacterial metabolism. by Tingting Wang (123983)

Subjects:

Effect of adding rhVEGF-A (-121 or -165) on the concentrations of VEGF-A121 and VEGF-A165 in plasma samples. by Masashi Okawa (8951294)

Subjects:

IFA abrogated capsule-associated hypermucoviscosity phenotypes of hypervirulent <i>K</i>. <i>pneumoniae</i>. by Tingting Wang (123983)

Subjects:

Exploring the correlation between systemic inflammation biomarkers and HCV infection (logarithm base 2). by Lu Han (151620)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

IFA effectively reduced the production of <i>K</i>. <i>pneumoniae</i> capsule. by Tingting Wang (123983)

Subjects:

IFA sensitized hypervirulent <i>K</i>. <i>pneumoniae</i> to complement-mediated killing by inhibiting capsule. by Tingting Wang (123983)

Subjects:

IFA disarmed capsule-mediated immune evasion. by Tingting Wang (123983)

Subjects:

Threshold effect analysis of systemic inflammatory biomarkers on hepatitis C using two-piece wise linear regression. by Lu Han (151620)

Subjects:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

Subjects:

The original data for the figures. by Masashi Okawa (8951294)

Subjects:

Exclusion and enrollment summary from NHANES. by Lu Han (151620)

Subjects:

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

VEGF-A121, VEGF-A165, and VEGF-A contents per unit platelets. by Masashi Okawa (8951294)

Subjects:

Validation of distinct contribution of capsule and hypercapsule-associated HMV in IFA-conferred protection against hvKP infection using a <i>ΔrmpD</i>-K7 mutant. by Tingting Wang (123983)

Subjects: